Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …

Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of
personalized treatment for cancer patients. The nearly simultaneous discovery of a …

Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common …

Accurate risk stratification of gastrointestinal stromal tumors (GISTs) has become
increasingly important owing to emerging adjuvant systemic treatments. All GISTs have …

Abstract Context.—Gastrointestinal stromal tumors (GISTs) are specific, generally Kit
(CD117)-positive, mesenchymal tumors of the gastrointestinal tract encompassing a majority …

The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment
recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice …

Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the
gastrointestinal (GI) tract. Soon after GIST was recognized as a tumor driven by a KIT or …

Importance Little is known about whether the duration of adjuvant imatinib influences the
prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet …

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of
mesenchymal origin and a compelling clinical and biologic model for the rational …